ClinicalTrials.gg
Drug

Tazemetostat clinical trials

Also written EPZ-6438, E7438 and Tazverik.

studies test it
43
open now
2
in phase 3
1
first study started
2013

How each study uses tazemetostat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the tazemetostat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
23 Jan 2020 · TAZVERIK · NDA 211723 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Tazemetostat
38
E 7438
6

Brand

Tazverik
13

Development codes

EPZ-6438
24
E7438
16
IPN60200
8

Studies by the year they started

43 studies that test it; most in 2023 (9)

Studies that test tazemetostat, by start year
YearStudies
20131
20141
20151
20164
20174
20183
20194
20203
20214
20224
20239
20243
20252

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
24
Phase 2
25
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 17 · Other 26

Epizyme, Inc. (13) · National Cancer Institute (NCI) (7) · Weill Medical College of Cornell University (2) · Eisai Co., Ltd. (2) · City of Hope Medical Center (2) · Northwestern University (1) · The Lymphoma Academic Research Organisation (1) · University of Florida (1)

Often tested with

Tested in the same studies.

Rituximab (3) · Palbociclib (2) · Belinostat (1) · Ensartinib (1) · Erdafitinib (1) · Ivosidenib (1) · Larotrectinib (1) · Olaparib (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 5, 1 in phase 3

Studies that test tazemetostat, phase 3 first.

Studies

Open first, then newest update. How each study uses tazemetostat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 43

See all 43 studies that test tazemetostat →

Given beside what is tested · 10 — tazemetostat is usual care or a partner of the new treatment

Codes

What other systems call tazemetostat · ClinicalTrials.gg INT000126

  • MeSH (NLM) C000593333tazemetostatConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) Q40W93WPE1TAZEMETOSTATConfirmed FDA, NLM, Wikidata
  • RxNorm 2274378One source FDA
  • Wikidata Q27088941tazemetostatConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C107506TazemetostatOne source FDA
  • DrugBank DB12887One source Wikidata

Also registered as tazemetostat dihydrobromide (UNII X536WKK41G), tazemetostat hydrobromide (UNII 6P89T5M073 · RxNorm 2274379), tazemetostat hydrochloride (UNII 1L6UQ905WM) and tazemetostat trihydrochloride (UNII 272LA4Y8S8).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.